By Crystal Phend, Senior Staff Writer, MedPage Today
Published: November 01, 2012
Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston and Dorothy Caputo, MA, BSN, RN, Nurse Planner

The combination of the biologic lapatinib (Tykerb) and capecitabine (Xeloda) chemotherapy appears to shrink brain metastases from HER2-positive breast cancer without need for radiation, a phase II trial showed.

Two-thirds of patients saw their previously-untreated brain lesions shrink by at least half with the treatment regimen, Thomas Bachelot, MD, of the Centre Léon Bérard in Lyon, France, and colleagues found in the LANDSCAPE trial.… [Continue Reading]